This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Diabetic retinopathy remains a major cause of vision loss among working-age individuals worldwide. While chronic hyperglycemia is a well-known risk factor, the study sheds light on the role of acute ...

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

British number one blind golfer Billy McAllister recalls his journey in the sport after completely losing his eyesight in ...

Original Article Archive Diabetic Retinopathy Author: Myron Yanoff, M.D. Author Info & Affiliations Published June 16, 1966 N Engl J Med 1966;274: 1344 - 1349 ...